| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Leukemia, Myeloid, Acute | 101 | 2023 | 114 | 17.410 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 46 | 2022 | 71 | 7.830 |
Why?
|
| Down Syndrome | 19 | 2023 | 39 | 3.560 |
Why?
|
| Cytarabine | 19 | 2022 | 24 | 2.960 |
Why?
|
| Child | 120 | 2023 | 3146 | 2.870 |
Why?
|
| Infant | 81 | 2023 | 1396 | 2.850 |
Why?
|
| Humans | 148 | 2023 | 6599 | 2.820 |
Why?
|
| Child, Preschool | 88 | 2023 | 1459 | 2.790 |
Why?
|
| Male | 95 | 2023 | 3197 | 2.450 |
Why?
|
| Female | 93 | 2023 | 3436 | 2.350 |
Why?
|
| Prognosis | 44 | 2023 | 209 | 2.240 |
Why?
|
| Adolescent | 79 | 2023 | 2087 | 2.160 |
Why?
|
| Biomarkers, Tumor | 12 | 2022 | 61 | 2.100 |
Why?
|
| Leukemia, Myeloid | 10 | 2021 | 10 | 1.890 |
Why?
|
| Treatment Outcome | 37 | 2023 | 624 | 1.830 |
Why?
|
| Aminoglycosides | 14 | 2022 | 17 | 1.830 |
Why?
|
| Antibodies, Monoclonal, Humanized | 14 | 2022 | 31 | 1.810 |
Why?
|
| Mutation | 20 | 2023 | 194 | 1.760 |
Why?
|
| Disease-Free Survival | 28 | 2023 | 45 | 1.600 |
Why?
|
| Young Adult | 46 | 2023 | 652 | 1.580 |
Why?
|
| Drug Resistance, Neoplasm | 8 | 2021 | 27 | 1.430 |
Why?
|
| Myelodysplastic Syndromes | 6 | 2022 | 11 | 1.350 |
Why?
|
| Antineoplastic Agents | 10 | 2021 | 57 | 1.320 |
Why?
|
| Neoplasm Recurrence, Local | 7 | 2021 | 33 | 1.270 |
Why?
|
| Infant, Newborn | 33 | 2022 | 790 | 1.260 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 11 | 2022 | 50 | 1.250 |
Why?
|
| Myeloproliferative Disorders | 7 | 2013 | 11 | 1.250 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 6 | 2019 | 60 | 1.160 |
Why?
|
| Clinical Trials, Phase III as Topic | 5 | 2017 | 10 | 1.140 |
Why?
|
| Myeloid-Lymphoid Leukemia Protein | 3 | 2021 | 7 | 1.080 |
Why?
|
| Daunorubicin | 8 | 2022 | 8 | 1.010 |
Why?
|
| Risk Factors | 21 | 2021 | 460 | 0.980 |
Why?
|
| Recurrence | 16 | 2022 | 115 | 0.980 |
Why?
|
| Histone-Lysine N-Methyltransferase | 2 | 2021 | 9 | 0.960 |
Why?
|
| Polymorphism, Single Nucleotide | 10 | 2022 | 340 | 0.950 |
Why?
|
| Adult | 33 | 2022 | 1233 | 0.930 |
Why?
|
| Gene Rearrangement | 2 | 2021 | 8 | 0.930 |
Why?
|
| Antimetabolites, Antineoplastic | 3 | 2021 | 23 | 0.910 |
Why?
|
| Medical Oncology | 5 | 2019 | 18 | 0.900 |
Why?
|
| Salvage Therapy | 3 | 2019 | 8 | 0.890 |
Why?
|
| Remission Induction | 13 | 2022 | 25 | 0.870 |
Why?
|
| Leukemia, Megakaryoblastic, Acute | 6 | 2013 | 6 | 0.850 |
Why?
|
| Kaplan-Meier Estimate | 14 | 2017 | 28 | 0.800 |
Why?
|
| Clinical Trials as Topic | 8 | 2021 | 44 | 0.790 |
Why?
|
| Bortezomib | 7 | 2023 | 10 | 0.770 |
Why?
|
| fms-Like Tyrosine Kinase 3 | 8 | 2022 | 8 | 0.760 |
Why?
|
| Gene Expression Profiling | 8 | 2023 | 109 | 0.730 |
Why?
|
| Neutropenia | 3 | 2016 | 13 | 0.710 |
Why?
|
| Survival Rate | 15 | 2022 | 84 | 0.700 |
Why?
|
| Follow-Up Studies | 12 | 2022 | 315 | 0.690 |
Why?
|
| Gene Expression Regulation, Leukemic | 6 | 2017 | 9 | 0.660 |
Why?
|
| Antibiotics, Antineoplastic | 2 | 2020 | 8 | 0.660 |
Why?
|
| Sialic Acid Binding Ig-like Lectin 3 | 6 | 2022 | 6 | 0.650 |
Why?
|
| Randomized Controlled Trials as Topic | 3 | 2017 | 62 | 0.650 |
Why?
|
| Multicenter Studies as Topic | 2 | 2017 | 17 | 0.650 |
Why?
|
| Leukemia, Promyelocytic, Acute | 4 | 2022 | 4 | 0.650 |
Why?
|
| Opportunistic Infections | 2 | 2015 | 7 | 0.620 |
Why?
|
| Central Nervous System Diseases | 1 | 2017 | 2 | 0.610 |
Why?
|
| Bone Marrow Transplantation | 6 | 2012 | 17 | 0.570 |
Why?
|
| Comparative Effectiveness Research | 2 | 2015 | 6 | 0.570 |
Why?
|
| Child Health Services | 2 | 2015 | 24 | 0.550 |
Why?
|
| Induction Chemotherapy | 3 | 2022 | 4 | 0.550 |
Why?
|
| Transcriptome | 7 | 2022 | 50 | 0.540 |
Why?
|
| Isocitrate Dehydrogenase | 4 | 2023 | 7 | 0.540 |
Why?
|
| Anti-Bacterial Agents | 2 | 2015 | 238 | 0.520 |
Why?
|
| Bacterial Infections | 3 | 2013 | 27 | 0.490 |
Why?
|
| Neoplasm, Residual | 7 | 2021 | 8 | 0.480 |
Why?
|
| MicroRNAs | 3 | 2019 | 26 | 0.480 |
Why?
|
| Antibiotic Prophylaxis | 2 | 2013 | 28 | 0.470 |
Why?
|
| Palliative Care | 1 | 2013 | 17 | 0.460 |
Why?
|
| United States | 6 | 2022 | 646 | 0.450 |
Why?
|
| Acute Disease | 9 | 2022 | 71 | 0.440 |
Why?
|
| Medical Record Linkage | 1 | 2012 | 1 | 0.440 |
Why?
|
| Medical Records Systems, Computerized | 1 | 2012 | 4 | 0.430 |
Why?
|
| Pediatrics | 5 | 2019 | 170 | 0.430 |
Why?
|
| Streptococcal Infections | 3 | 2013 | 19 | 0.430 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 3 | 2021 | 4 | 0.410 |
Why?
|
| Neoplasms | 2 | 2012 | 119 | 0.390 |
Why?
|
| RNA, Messenger | 6 | 2019 | 107 | 0.390 |
Why?
|
| Proportional Hazards Models | 7 | 2021 | 34 | 0.380 |
Why?
|
| Etoposide | 8 | 2022 | 11 | 0.380 |
Why?
|
| Genotype | 9 | 2019 | 395 | 0.380 |
Why?
|
| DNA-Binding Proteins | 4 | 2015 | 35 | 0.370 |
Why?
|
| Pilot Projects | 6 | 2017 | 124 | 0.370 |
Why?
|
| Oncogene Proteins, Fusion | 3 | 2021 | 7 | 0.360 |
Why?
|
| Flow Cytometry | 8 | 2020 | 26 | 0.360 |
Why?
|
| Anthracyclines | 2 | 2021 | 7 | 0.360 |
Why?
|
| CCAAT-Enhancer-Binding Proteins | 2 | 2021 | 2 | 0.350 |
Why?
|
| Retrospective Studies | 14 | 2023 | 1251 | 0.340 |
Why?
|
| STAT3 Transcription Factor | 2 | 2021 | 7 | 0.340 |
Why?
|
| Transcription Factors | 4 | 2013 | 46 | 0.320 |
Why?
|
| DNA Copy Number Variations | 3 | 2017 | 31 | 0.320 |
Why?
|
| Hospitals, Pediatric | 3 | 2015 | 178 | 0.310 |
Why?
|
| Time Factors | 3 | 2021 | 241 | 0.310 |
Why?
|
| Busulfan | 4 | 2021 | 4 | 0.300 |
Why?
|
| Rhabdomyosarcoma | 2 | 2021 | 5 | 0.300 |
Why?
|
| Adverse Drug Reaction Reporting Systems | 2 | 2017 | 13 | 0.290 |
Why?
|
| Stem Cell Transplantation | 6 | 2022 | 11 | 0.290 |
Why?
|
| Dexamethasone | 2 | 2019 | 30 | 0.280 |
Why?
|
| Health Care Surveys | 2 | 2009 | 32 | 0.280 |
Why?
|
| Risk Assessment | 3 | 2021 | 130 | 0.280 |
Why?
|
| Immunophenotyping | 4 | 2019 | 7 | 0.270 |
Why?
|
| Patient Discharge | 2 | 2016 | 58 | 0.270 |
Why?
|
| Mycoses | 4 | 2013 | 11 | 0.270 |
Why?
|
| Graft vs Host Disease | 3 | 2022 | 11 | 0.270 |
Why?
|
| Genes, Wilms Tumor | 3 | 2019 | 3 | 0.260 |
Why?
|
| Incidence | 5 | 2018 | 125 | 0.250 |
Why?
|
| Prospective Studies | 7 | 2016 | 508 | 0.250 |
Why?
|
| Neoplastic Stem Cells | 2 | 2022 | 10 | 0.240 |
Why?
|
| Mitoxantrone | 3 | 2019 | 6 | 0.240 |
Why?
|
| Cell Cycle Proteins | 1 | 2023 | 15 | 0.230 |
Why?
|
| Gene Expression | 2 | 2014 | 60 | 0.230 |
Why?
|
| RNA, Long Noncoding | 1 | 2023 | 14 | 0.230 |
Why?
|
| Transplantation Conditioning | 3 | 2022 | 4 | 0.220 |
Why?
|
| Peripheral Blood Stem Cell Transplantation | 2 | 2014 | 3 | 0.220 |
Why?
|
| Proteomics | 1 | 2022 | 19 | 0.220 |
Why?
|
| DNA Damage | 1 | 2022 | 6 | 0.220 |
Why?
|
| Signal Transduction | 2 | 2015 | 107 | 0.210 |
Why?
|
| Tretinoin | 1 | 2022 | 2 | 0.210 |
Why?
|
| Leukemia | 3 | 2012 | 17 | 0.210 |
Why?
|
| Hematopoiesis | 1 | 2002 | 3 | 0.210 |
Why?
|
| Cytogenetic Analysis | 2 | 2023 | 3 | 0.210 |
Why?
|
| NF-kappa B | 1 | 2021 | 14 | 0.210 |
Why?
|
| Basic-Leucine Zipper Transcription Factors | 1 | 2021 | 2 | 0.210 |
Why?
|
| STAT5 Transcription Factor | 1 | 2021 | 6 | 0.200 |
Why?
|
| MAP Kinase Signaling System | 1 | 2021 | 5 | 0.200 |
Why?
|
| Rhabdomyosarcoma, Embryonal | 1 | 2021 | 3 | 0.200 |
Why?
|
| Rhabdomyosarcoma, Alveolar | 1 | 2021 | 4 | 0.200 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2021 | 14 | 0.200 |
Why?
|
| Leukemia, Erythroblastic, Acute | 1 | 2020 | 1 | 0.200 |
Why?
|
| Cohort Studies | 6 | 2019 | 264 | 0.200 |
Why?
|
| Dexrazoxane | 1 | 2020 | 1 | 0.190 |
Why?
|
| Cardiotonic Agents | 1 | 2020 | 5 | 0.190 |
Why?
|
| Age Factors | 5 | 2013 | 203 | 0.190 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2020 | 7 | 0.190 |
Why?
|
| Phenotype | 2 | 2019 | 233 | 0.190 |
Why?
|
| Doxorubicin | 1 | 2020 | 17 | 0.190 |
Why?
|
| Wnt Proteins | 1 | 2020 | 11 | 0.190 |
Why?
|
| beta Catenin | 1 | 2020 | 9 | 0.190 |
Why?
|
| Ventricular Function, Left | 1 | 2020 | 25 | 0.190 |
Why?
|
| Reference Standards | 1 | 2020 | 15 | 0.190 |
Why?
|
| Vincristine | 1 | 2019 | 8 | 0.180 |
Why?
|
| Leukemia, Biphenotypic, Acute | 1 | 2019 | 1 | 0.180 |
Why?
|
| Asparaginase | 1 | 2019 | 15 | 0.180 |
Why?
|
| Polyethylene Glycols | 1 | 2019 | 12 | 0.180 |
Why?
|
| Core Binding Factors | 1 | 2019 | 1 | 0.180 |
Why?
|
| Proto-Oncogene Proteins c-kit | 1 | 2019 | 5 | 0.180 |
Why?
|
| Cell Transformation, Neoplastic | 2 | 2013 | 14 | 0.180 |
Why?
|
| Multivariate Analysis | 4 | 2021 | 74 | 0.170 |
Why?
|
| Cardiotoxicity | 1 | 2018 | 2 | 0.170 |
Why?
|
| Hemorrhage | 1 | 2019 | 18 | 0.170 |
Why?
|
| DNA Methylation | 3 | 2017 | 108 | 0.170 |
Why?
|
| Gene Duplication | 2 | 2015 | 10 | 0.170 |
Why?
|
| Thrombosis | 1 | 2019 | 15 | 0.170 |
Why?
|
| Neoplasm Staging | 3 | 2014 | 31 | 0.160 |
Why?
|
| Quality of Life | 2 | 2017 | 131 | 0.160 |
Why?
|
| Monocytes | 1 | 2018 | 9 | 0.160 |
Why?
|
| Alternative Splicing | 2 | 2018 | 17 | 0.160 |
Why?
|
| Arsenicals | 1 | 2017 | 1 | 0.160 |
Why?
|
| Oxides | 1 | 2017 | 1 | 0.160 |
Why?
|
| Hepatic Veno-Occlusive Disease | 1 | 2017 | 6 | 0.150 |
Why?
|
| Survivors | 1 | 2017 | 17 | 0.150 |
Why?
|
| Telomere | 1 | 2016 | 3 | 0.150 |
Why?
|
| Neutrophils | 1 | 2016 | 11 | 0.150 |
Why?
|
| Critical Care | 1 | 2016 | 12 | 0.150 |
Why?
|
| Intensive Care Units, Pediatric | 1 | 2016 | 10 | 0.150 |
Why?
|
| Disease Progression | 3 | 2014 | 104 | 0.150 |
Why?
|
| Receptors, Colony-Stimulating Factor | 1 | 2016 | 1 | 0.140 |
Why?
|
| Dose-Response Relationship, Drug | 4 | 2021 | 92 | 0.140 |
Why?
|
| Information Storage and Retrieval | 1 | 2015 | 5 | 0.140 |
Why?
|
| Genomics | 1 | 2016 | 86 | 0.140 |
Why?
|
| Thioguanine | 2 | 2013 | 8 | 0.140 |
Why?
|
| Antifungal Agents | 2 | 2013 | 13 | 0.140 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2015 | 17 | 0.130 |
Why?
|
| Loss of Heterozygosity | 1 | 2015 | 1 | 0.130 |
Why?
|
| Mouth Diseases | 1 | 1995 | 1 | 0.130 |
Why?
|
| Epigenesis, Genetic | 2 | 2013 | 64 | 0.130 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2017 | 51 | 0.130 |
Why?
|
| Blood Proteins | 1 | 2015 | 3 | 0.130 |
Why?
|
| Survival Analysis | 4 | 2017 | 46 | 0.130 |
Why?
|
| Drug Administration Schedule | 3 | 2012 | 40 | 0.130 |
Why?
|
| Health Information Systems | 1 | 2015 | 5 | 0.130 |
Why?
|
| Databases, Factual | 1 | 2015 | 105 | 0.130 |
Why?
|
| Genotyping Techniques | 1 | 2015 | 21 | 0.130 |
Why?
|
| Vancomycin | 1 | 1995 | 17 | 0.130 |
Why?
|
| Sepsis | 1 | 1995 | 22 | 0.130 |
Why?
|
| Immune System Diseases | 1 | 2014 | 6 | 0.130 |
Why?
|
| Hodgkin Disease | 1 | 2014 | 2 | 0.130 |
Why?
|
| Polymorphism, Genetic | 2 | 2010 | 89 | 0.130 |
Why?
|
| Bone Neoplasms | 2 | 1996 | 23 | 0.130 |
Why?
|
| Canada | 1 | 2014 | 31 | 0.130 |
Why?
|
| Diabetes Mellitus | 1 | 2014 | 21 | 0.130 |
Why?
|
| Transplantation, Homologous | 4 | 2022 | 20 | 0.130 |
Why?
|
| Suppressor of Cytokine Signaling Proteins | 1 | 2014 | 2 | 0.120 |
Why?
|
| Translocation, Genetic | 1 | 2014 | 4 | 0.120 |
Why?
|
| Chromosomes, Human, Pair 6 | 1 | 2014 | 4 | 0.120 |
Why?
|
| Chromosomes, Human, Pair 9 | 1 | 2014 | 5 | 0.120 |
Why?
|
| Genome-Wide Association Study | 1 | 2015 | 181 | 0.120 |
Why?
|
| Myeloablative Agonists | 1 | 2013 | 1 | 0.120 |
Why?
|
| Viridans Streptococci | 1 | 2013 | 2 | 0.120 |
Why?
|
| Inhibitor of Apoptosis Proteins | 1 | 2013 | 1 | 0.120 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 4 | 2015 | 64 | 0.120 |
Why?
|
| Chromosomes, Human, Pair 5 | 1 | 2013 | 4 | 0.120 |
Why?
|
| Sex Factors | 2 | 2010 | 71 | 0.120 |
Why?
|
| Integrin alpha5 | 1 | 2013 | 1 | 0.120 |
Why?
|
| Prevalence | 5 | 2012 | 145 | 0.120 |
Why?
|
| RNA Splicing | 1 | 2013 | 11 | 0.120 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 1993 | 1 | 0.120 |
Why?
|
| Tissue Donors | 1 | 1993 | 28 | 0.120 |
Why?
|
| Alkylating Agents | 1 | 2013 | 1 | 0.110 |
Why?
|
| Middle Aged | 4 | 2019 | 648 | 0.110 |
Why?
|
| Research | 1 | 2012 | 11 | 0.110 |
Why?
|
| Accreditation | 1 | 2012 | 4 | 0.110 |
Why?
|
| Alleles | 3 | 2019 | 197 | 0.110 |
Why?
|
| Genetic Association Studies | 1 | 2013 | 53 | 0.110 |
Why?
|
| Azepines | 1 | 2012 | 1 | 0.110 |
Why?
|
| Polyploidy | 1 | 2012 | 1 | 0.110 |
Why?
|
| Megakaryocytes | 1 | 2012 | 3 | 0.110 |
Why?
|
| Small Molecule Libraries | 1 | 2012 | 5 | 0.110 |
Why?
|
| Pyrimidines | 1 | 2012 | 6 | 0.110 |
Why?
|
| Leukocytosis | 1 | 2012 | 2 | 0.110 |
Why?
|
| Immunosuppressive Agents | 1 | 2013 | 37 | 0.110 |
Why?
|
| Leukocyte Elastase | 1 | 2012 | 1 | 0.110 |
Why?
|
| Drug Discovery | 1 | 2012 | 3 | 0.110 |
Why?
|
| Registries | 1 | 2012 | 85 | 0.110 |
Why?
|
| Organizational Objectives | 1 | 2012 | 1 | 0.110 |
Why?
|
| National Cancer Institute (U.S.) | 1 | 2012 | 3 | 0.110 |
Why?
|
| Nuclear Pore Complex Proteins | 2 | 2023 | 2 | 0.110 |
Why?
|
| Costs and Cost Analysis | 1 | 2012 | 6 | 0.110 |
Why?
|
| Antigens, Differentiation, Myelomonocytic | 1 | 2012 | 1 | 0.110 |
Why?
|
| Cooperative Behavior | 1 | 2012 | 26 | 0.110 |
Why?
|
| Antigens, CD | 1 | 2012 | 8 | 0.110 |
Why?
|
| Combined Modality Therapy | 4 | 2014 | 51 | 0.110 |
Why?
|
| Fusarium | 1 | 1991 | 1 | 0.110 |
Why?
|
| Regression Analysis | 3 | 2017 | 56 | 0.100 |
Why?
|
| Amsacrine | 1 | 2011 | 1 | 0.100 |
Why?
|
| Amifostine | 1 | 2011 | 1 | 0.100 |
Why?
|
| Radiation-Protective Agents | 1 | 2011 | 1 | 0.100 |
Why?
|
| Genes, ras | 1 | 2011 | 1 | 0.100 |
Why?
|
| Aged | 3 | 2020 | 375 | 0.100 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2022 | 5 | 0.100 |
Why?
|
| Cognition Disorders | 1 | 1991 | 13 | 0.100 |
Why?
|
| Cytogenetics | 1 | 2010 | 2 | 0.100 |
Why?
|
| Fibroma | 1 | 2010 | 2 | 0.100 |
Why?
|
| Tongue Neoplasms | 1 | 2010 | 2 | 0.100 |
Why?
|
| Integrin alpha4beta1 | 1 | 2010 | 1 | 0.090 |
Why?
|
| Brain Neoplasms | 1 | 1991 | 44 | 0.090 |
Why?
|
| Abdominal Neoplasms | 1 | 2010 | 5 | 0.090 |
Why?
|
| Codon | 1 | 2010 | 2 | 0.090 |
Why?
|
| Biomarkers | 2 | 2022 | 120 | 0.090 |
Why?
|
| Glioblastoma | 1 | 1990 | 17 | 0.090 |
Why?
|
| Laparotomy | 1 | 2010 | 21 | 0.090 |
Why?
|
| Burkitt Lymphoma | 1 | 2010 | 2 | 0.090 |
Why?
|
| Hematopoietic Stem Cell Mobilization | 1 | 2010 | 2 | 0.090 |
Why?
|
| Heterocyclic Compounds | 1 | 2010 | 3 | 0.090 |
Why?
|
| Intestinal Obstruction | 1 | 2010 | 19 | 0.090 |
Why?
|
| Cell Line, Tumor | 2 | 2021 | 87 | 0.090 |
Why?
|
| DNA | 2 | 2022 | 39 | 0.090 |
Why?
|
| Animals | 3 | 2020 | 563 | 0.090 |
Why?
|
| Thrombopoiesis | 1 | 2009 | 1 | 0.090 |
Why?
|
| Body Mass Index | 1 | 2010 | 155 | 0.090 |
Why?
|
| Professional Practice | 1 | 2009 | 4 | 0.090 |
Why?
|
| Analgesia | 1 | 1989 | 1 | 0.090 |
Why?
|
| Nitrous Oxide | 1 | 1989 | 2 | 0.090 |
Why?
|
| Colony-Stimulating Factors | 1 | 2008 | 1 | 0.090 |
Why?
|
| Age of Onset | 2 | 2011 | 27 | 0.080 |
Why?
|
| Congenital Abnormalities | 1 | 2008 | 11 | 0.080 |
Why?
|
| Dietary Supplements | 1 | 2008 | 18 | 0.080 |
Why?
|
| Respiratory Syncytial Virus Infections | 1 | 2008 | 41 | 0.080 |
Why?
|
| Acetone | 1 | 1988 | 1 | 0.080 |
Why?
|
| Repressor Proteins | 2 | 2019 | 12 | 0.080 |
Why?
|
| Logistic Models | 3 | 2014 | 91 | 0.080 |
Why?
|
| Janus Kinase 3 | 1 | 2007 | 1 | 0.080 |
Why?
|
| Receptors, Thrombopoietin | 1 | 2007 | 1 | 0.080 |
Why?
|
| Janus Kinase 2 | 1 | 2007 | 8 | 0.080 |
Why?
|
| Emergency Service, Hospital | 1 | 1989 | 129 | 0.080 |
Why?
|
| Leukemia, Radiation-Induced | 1 | 2006 | 1 | 0.070 |
Why?
|
| Cell Proliferation | 2 | 2020 | 55 | 0.070 |
Why?
|
| Leukocyte Count | 2 | 2019 | 6 | 0.070 |
Why?
|
| Electronic Health Records | 2 | 2017 | 61 | 0.070 |
Why?
|
| Mice | 2 | 2020 | 290 | 0.070 |
Why?
|
| Reproducibility of Results | 2 | 2017 | 197 | 0.070 |
Why?
|
| Treatment Failure | 2 | 2016 | 17 | 0.070 |
Why?
|
| Case-Control Studies | 3 | 2013 | 202 | 0.070 |
Why?
|
| Decision Making | 1 | 2005 | 34 | 0.060 |
Why?
|
| Gene Frequency | 2 | 2018 | 88 | 0.060 |
Why?
|
| Genetic Predisposition to Disease | 3 | 2013 | 215 | 0.060 |
Why?
|
| Adenine Nucleotides | 2 | 2014 | 2 | 0.060 |
Why?
|
| Arabinonucleosides | 2 | 2014 | 2 | 0.060 |
Why?
|
| Retinoblastoma-Binding Protein 2 | 1 | 2023 | 1 | 0.060 |
Why?
|
| Nuclear Proteins | 2 | 2016 | 45 | 0.060 |
Why?
|
| Unfolded Protein Response | 1 | 2023 | 3 | 0.060 |
Why?
|
| Aged, 80 and over | 2 | 2016 | 150 | 0.060 |
Why?
|
| Real-Time Polymerase Chain Reaction | 2 | 2013 | 38 | 0.060 |
Why?
|
| Gene Fusion | 1 | 2023 | 2 | 0.060 |
Why?
|
| Mutation Rate | 1 | 2023 | 2 | 0.060 |
Why?
|
| Mutagenesis | 1 | 2003 | 4 | 0.060 |
Why?
|
| Protein Array Analysis | 1 | 2022 | 2 | 0.060 |
Why?
|
| RNA | 1 | 2022 | 14 | 0.060 |
Why?
|
| Proteins | 1 | 2022 | 22 | 0.060 |
Why?
|
| Drug Monitoring | 2 | 2013 | 19 | 0.050 |
Why?
|
| Tandem Repeat Sequences | 2 | 2014 | 4 | 0.050 |
Why?
|
| Phenylurea Compounds | 1 | 2022 | 1 | 0.050 |
Why?
|
| Unrelated Donors | 1 | 2022 | 1 | 0.050 |
Why?
|
| Myosin Heavy Chains | 1 | 2021 | 1 | 0.050 |
Why?
|
| Core Binding Factor beta Subunit | 1 | 2021 | 1 | 0.050 |
Why?
|
| Transcription Factor RelA | 1 | 2021 | 2 | 0.050 |
Why?
|
| Phosphorylation | 1 | 2021 | 21 | 0.050 |
Why?
|
| DNA Mutational Analysis | 3 | 2009 | 36 | 0.050 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2021 | 1 | 0.050 |
Why?
|
| Interleukin-13 | 1 | 2021 | 1 | 0.050 |
Why?
|
| Cryopreservation | 1 | 2021 | 4 | 0.050 |
Why?
|
| Culture Media, Conditioned | 1 | 2021 | 2 | 0.050 |
Why?
|
| MyoD Protein | 1 | 2021 | 4 | 0.050 |
Why?
|
| Transcriptional Activation | 1 | 2021 | 8 | 0.050 |
Why?
|
| Up-Regulation | 1 | 2021 | 25 | 0.050 |
Why?
|
| Tumor Microenvironment | 1 | 2021 | 14 | 0.050 |
Why?
|
| Point Mutation | 1 | 2021 | 4 | 0.050 |
Why?
|
| Sequence Analysis, RNA | 1 | 2021 | 23 | 0.050 |
Why?
|
| Bone Marrow | 2 | 2015 | 6 | 0.050 |
Why?
|
| Hemolysis | 1 | 2000 | 3 | 0.050 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2020 | 14 | 0.050 |
Why?
|
| Tumor Cells, Cultured | 1 | 2020 | 24 | 0.050 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2020 | 9 | 0.050 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2020 | 9 | 0.050 |
Why?
|
| Mice, Knockout | 1 | 2020 | 54 | 0.050 |
Why?
|
| Apoptosis | 1 | 2020 | 43 | 0.050 |
Why?
|
| Receptors, GABA-A | 1 | 2019 | 1 | 0.050 |
Why?
|
| World Health Organization | 1 | 2019 | 5 | 0.050 |
Why?
|
| Kruppel-Like Transcription Factors | 1 | 2019 | 6 | 0.040 |
Why?
|
| Exons | 1 | 2019 | 32 | 0.040 |
Why?
|
| Molecular Targeted Therapy | 1 | 2019 | 11 | 0.040 |
Why?
|
| Genes, p53 | 1 | 2019 | 4 | 0.040 |
Why?
|
| K562 Cells | 1 | 2018 | 3 | 0.040 |
Why?
|
| Echocardiography | 1 | 2018 | 78 | 0.040 |
Why?
|
| HEK293 Cells | 1 | 2018 | 30 | 0.040 |
Why?
|
| Chromosome Aberrations | 1 | 2017 | 5 | 0.040 |
Why?
|
| Bone Marrow Examination | 1 | 2017 | 1 | 0.040 |
Why?
|
| Consolidation Chemotherapy | 1 | 2017 | 1 | 0.040 |
Why?
|
| Historically Controlled Study | 1 | 2017 | 1 | 0.040 |
Why?
|
| Observer Variation | 1 | 2017 | 12 | 0.040 |
Why?
|
| Cluster Analysis | 1 | 2017 | 43 | 0.040 |
Why?
|
| Heterozygote | 1 | 2017 | 23 | 0.040 |
Why?
|
| Homozygote | 1 | 2017 | 18 | 0.040 |
Why?
|
| DNA, Neoplasm | 1 | 2017 | 7 | 0.040 |
Why?
|
| Gene Expression Regulation | 1 | 2018 | 98 | 0.040 |
Why?
|
| Genetic Markers | 1 | 2017 | 20 | 0.040 |
Why?
|
| Receptors, Cell Surface | 1 | 2017 | 6 | 0.040 |
Why?
|
| Methotrexate | 1 | 2017 | 27 | 0.040 |
Why?
|
| Health Status Indicators | 1 | 2017 | 8 | 0.040 |
Why?
|
| Hypothyroidism | 1 | 2017 | 4 | 0.040 |
Why?
|
| Genetic Testing | 1 | 2017 | 74 | 0.040 |
Why?
|
| Cell Adhesion Molecules, Neuronal | 1 | 2016 | 4 | 0.040 |
Why?
|
| Serine Endopeptidases | 1 | 2016 | 5 | 0.040 |
Why?
|
| Extracellular Matrix Proteins | 1 | 2016 | 13 | 0.040 |
Why?
|
| Nerve Tissue Proteins | 1 | 2016 | 24 | 0.040 |
Why?
|
| Carrier Proteins | 1 | 2016 | 32 | 0.040 |
Why?
|
| Chronic Disease | 1 | 2017 | 103 | 0.040 |
Why?
|
| Salivary Gland Neoplasms | 1 | 1996 | 1 | 0.040 |
Why?
|
| Salivary Glands, Minor | 1 | 1996 | 1 | 0.040 |
Why?
|
| Mortality | 1 | 2016 | 3 | 0.040 |
Why?
|
| Adenocarcinoma | 1 | 1996 | 8 | 0.030 |
Why?
|
| MEF2 Transcription Factors | 1 | 2015 | 1 | 0.030 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2016 | 44 | 0.030 |
Why?
|
| Pregnancy | 1 | 2016 | 203 | 0.030 |
Why?
|
| Dioxygenases | 1 | 2015 | 1 | 0.030 |
Why?
|
| Microarray Analysis | 1 | 2015 | 6 | 0.030 |
Why?
|
| Streptococcus | 1 | 1995 | 2 | 0.030 |
Why?
|
| Ointments | 1 | 1995 | 6 | 0.030 |
Why?
|
| Oral Hygiene | 1 | 1995 | 3 | 0.030 |
Why?
|
| Patient Readmission | 1 | 2016 | 66 | 0.030 |
Why?
|
| Quantitative Trait Loci | 1 | 2015 | 64 | 0.030 |
Why?
|
| Algorithms | 1 | 2015 | 103 | 0.030 |
Why?
|
| Ifosfamide | 1 | 2014 | 1 | 0.030 |
Why?
|
| Vinblastine | 1 | 2014 | 1 | 0.030 |
Why?
|
| Transplantation, Autologous | 1 | 2014 | 3 | 0.030 |
Why?
|
| Inpatients | 1 | 2015 | 44 | 0.030 |
Why?
|
| Length of Stay | 1 | 2016 | 227 | 0.030 |
Why?
|
| Age Distribution | 1 | 2014 | 31 | 0.030 |
Why?
|
| Boronic Acids | 1 | 2014 | 1 | 0.030 |
Why?
|
| Pyrazines | 1 | 2014 | 1 | 0.030 |
Why?
|
| Idarubicin | 1 | 2014 | 1 | 0.030 |
Why?
|
| Rabbits | 1 | 2014 | 5 | 0.030 |
Why?
|
| Genes, Neoplasm | 1 | 2014 | 4 | 0.030 |
Why?
|
| Neoplasm Proteins | 1 | 2014 | 29 | 0.030 |
Why?
|
| Gene Deletion | 1 | 2013 | 12 | 0.030 |
Why?
|
| Bayes Theorem | 1 | 2013 | 30 | 0.030 |
Why?
|
| Proto-Oncogenes | 1 | 2013 | 2 | 0.030 |
Why?
|
| RNA, Neoplasm | 1 | 2013 | 5 | 0.030 |
Why?
|
| Erythroid-Specific DNA-Binding Factors | 2 | 2003 | 2 | 0.030 |
Why?
|
| GATA1 Transcription Factor | 2 | 2003 | 2 | 0.030 |
Why?
|
| Neoadjuvant Therapy | 1 | 2013 | 6 | 0.030 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2013 | 18 | 0.030 |
Why?
|
| Precision Medicine | 1 | 2013 | 42 | 0.030 |
Why?
|
| Single-Cell Analysis | 1 | 2013 | 9 | 0.030 |
Why?
|
| Administration, Intravenous | 1 | 2013 | 3 | 0.030 |
Why?
|
| Area Under Curve | 1 | 2013 | 34 | 0.030 |
Why?
|
| 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine | 1 | 2012 | 1 | 0.030 |
Why?
|
| rho-Associated Kinases | 1 | 2012 | 1 | 0.030 |
Why?
|
| Protein Interaction Maps | 1 | 2012 | 1 | 0.030 |
Why?
|
| Aurora Kinases | 1 | 2012 | 1 | 0.030 |
Why?
|
| Aurora Kinase A | 1 | 2012 | 3 | 0.030 |
Why?
|
| Cell Differentiation | 1 | 2012 | 41 | 0.030 |
Why?
|
| Mice, Inbred C57BL | 1 | 2012 | 76 | 0.030 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2013 | 82 | 0.030 |
Why?
|
| Mutation, Missense | 1 | 2011 | 24 | 0.030 |
Why?
|
| Societies, Medical | 1 | 2011 | 43 | 0.030 |
Why?
|
| Education, Special | 1 | 1991 | 1 | 0.020 |
Why?
|
| Central Nervous System | 1 | 1991 | 7 | 0.020 |
Why?
|
| Research Design | 1 | 2011 | 64 | 0.020 |
Why?
|
| Attention Deficit Disorder with Hyperactivity | 1 | 1991 | 17 | 0.020 |
Why?
|
| Developmental Disabilities | 1 | 1991 | 38 | 0.020 |
Why?
|
| Glossectomy | 1 | 2010 | 1 | 0.020 |
Why?
|
| Microscopy | 1 | 2010 | 3 | 0.020 |
Why?
|
| Immunohistochemistry | 1 | 2010 | 36 | 0.020 |
Why?
|
| Karyotyping | 1 | 2010 | 8 | 0.020 |
Why?
|
| Diagnosis, Differential | 1 | 2010 | 74 | 0.020 |
Why?
|
| Filgrastim | 1 | 2010 | 2 | 0.020 |
Why?
|
| Benzylamines | 1 | 2010 | 2 | 0.020 |
Why?
|
| Recombinant Proteins | 1 | 2010 | 47 | 0.020 |
Why?
|
| International Cooperation | 1 | 2009 | 9 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2010 | 114 | 0.020 |
Why?
|
| Drug Utilization | 1 | 2009 | 13 | 0.020 |
Why?
|
| Dietary Fats | 1 | 1989 | 5 | 0.020 |
Why?
|
| Edema | 1 | 1989 | 8 | 0.020 |
Why?
|
| Mucocutaneous Lymph Node Syndrome | 1 | 1989 | 9 | 0.020 |
Why?
|
| Bilirubin | 1 | 1989 | 25 | 0.020 |
Why?
|
| Gallbladder Diseases | 1 | 1989 | 13 | 0.020 |
Why?
|
| Virus Diseases | 1 | 2009 | 11 | 0.020 |
Why?
|
| Respiratory Syncytial Viruses | 1 | 2008 | 16 | 0.020 |
Why?
|
| Pain Measurement | 1 | 1989 | 44 | 0.020 |
Why?
|
| Interviews as Topic | 1 | 2008 | 36 | 0.020 |
Why?
|
| Vitamins | 1 | 2008 | 10 | 0.020 |
Why?
|
| Parents | 1 | 2006 | 149 | 0.020 |
Why?
|
| Alberta | 1 | 2000 | 1 | 0.010 |
Why?
|
| Cyclophosphamide | 1 | 2000 | 8 | 0.010 |
Why?
|
| Texas | 1 | 2000 | 16 | 0.010 |
Why?
|
| Missouri | 1 | 2000 | 78 | 0.010 |
Why?
|
| Chimera | 1 | 1997 | 2 | 0.010 |
Why?
|
| Repetitive Sequences, Nucleic Acid | 1 | 1997 | 3 | 0.010 |
Why?
|
| Staining and Labeling | 1 | 1996 | 1 | 0.010 |
Why?
|
| Immunoenzyme Techniques | 1 | 1996 | 9 | 0.010 |
Why?
|